Richard A. Colvin - Sep 30, 2024 Form 4 Insider Report for bluebird bio, Inc. (BLUE)

Role
Chief Medical Officer
Signature
/s/ Sydney Gaylin, Attorney-in-Fact
Stock symbol
BLUE
Transactions as of
Sep 30, 2024
Transactions value $
$0
Form type
4
Date filed
10/2/2024, 04:06 PM
Previous filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLUE Common Stock Award $0 +50K +42.24% $0.00 168K Sep 30, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units for common stock vest over a four-year period at the rate of 25% on each of March 1, 2025, March 1, 2026, March 1, 2027 and March 1, 2028. These restricted stock units were approved during the Issuer's regular annual review cycle for 2024 with a delayed date of issuance.